Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy argenx stock | $296.02

Learn how to easily invest in argenx stock.

argenx SE is a biotechnology business based in the US. argenx shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx employs 336 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in argenx

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARGX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

argenx stock price (NASDAQ: ARGX)

Use our graph to track the performance of ARGX stocks over time.

argenx shares at a glance

Information last updated 2021-10-16.
Latest market close$296.02
52-week range$244.98 - $382.15
50-day moving average $314.74
200-day moving average $299.99
Wall St. target price$351.94
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.89

Buy argenx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy argenx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

argenx price performance over time

Historical closes compared with the close of $296.02 from 2021-10-20

1 week (2021-10-14) 0.29%
1 month (2021-09-21) -6.43%
3 months (2021-07-21) -7.20%
6 months (2021-04-21) 2.31%
1 year (2020-10-21) 15.27%
2 years (2019-10-21) 157.72%
3 years (2018-10-19) 263.66%
5 years (2016-10-17) N/A

argenx financials

Revenue TTM $517.8 million
Gross profit TTM $-270,945,000
Return on assets TTM -4.36%
Return on equity TTM -14.14%
Profit margin -65.15%
Book value $57.43
Market capitalisation $15.4 billion

TTM: trailing 12 months

Shorting argenx shares

There are currently 896,000 argenx shares held short by investors – that's known as argenx's "short interest". This figure is 8.6% up from 825,234 last month.

There are a few different ways that this level of interest in shorting argenx shares can be evaluated.

argenx's "short interest ratio" (SIR)

argenx's "short interest ratio" (SIR) is the quantity of argenx shares currently shorted divided by the average quantity of argenx shares traded daily (recently around 198230.08849558). argenx's SIR currently stands at 4.52. In other words for every 100,000 argenx shares traded daily on the market, roughly 4520 shares are currently held short.

However argenx's short interest can also be evaluated against the total number of argenx shares, or, against the total number of tradable argenx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case argenx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 argenx shares in existence, roughly 20 shares are currently held short) or 0.0193% of the tradable shares (for every 100,000 tradable argenx shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against argenx.

Find out more about how you can short argenx stock.

argenx share dividends

We're not expecting argenx to pay a dividend over the next 12 months.

argenx share price volatility

Over the last 12 months, argenx's shares have ranged in value from as little as $244.98 up to $382.15. A popular way to gauge a stock's volatility is its "beta".

ARGX.US volatility(beta: 0.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx's is 0.8087. This would suggest that argenx's shares are less volatile than average (for this exchange).

argenx overview

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S. À. R.

Frequently asked questions

What percentage of argenx is owned by institutions?
Currently 57.09% of argenx shares are held by institutions.
How many people work for argenx?
Latest data suggests 336 work at argenx.
When does the fiscal year end for argenx?
argenx's fiscal year ends in December.
Where is argenx based?
argenx's address is: Willemstraat 5, Breda, Netherlands, 4811 AH
What is argenx's ISIN number?
argenx's international securities identification number is: US04016X1019
What is argenx's CUSIP number?
argenx's Committee on Uniform Securities Identification Procedures number is: 04016X101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site